Grp94 has emerged as a promising target for the treatment of metastatic cancer and primary open-angle glaucoma, due to the lack of toxicity resulting from Grp94 inhibition and knockout in mammalian cells [18,94,95]. Here, HSP90B1 is linked to open-angle glaucoma.